for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Theratechnologies Inc

TH.TO

Latest Trade

4.85CAD

Change

-0.05(-1.02%)

Volume

57,765

Today's Range

4.73

 - 

5.12

52 Week Range

4.71

 - 

9.74

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.90
Open
4.95
Volume
57,765
3M AVG Volume
1.51
Today's High
5.12
Today's Low
4.73
52 Week High
9.74
52 Week Low
4.71
Shares Out (MIL)
76.95
Market Cap (MIL)
375.40
Forward P/E
-85.66
Dividend (Yield %)
--

Latest Developments

More

Theratechnologies Will Maintain Its Common Share Listing On Toronto Stock Exchange Under Symbol "TH"

Theratechnologies Reports Q3 Loss Per Share Of $0.02

European Commission Approves Trogarzo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Theratechnologies Inc

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.

Industry

Biotechnology & Drugs

Contact Info

2015 Peel St 5th Floor

+1.514.3367800

http://www.theratech.com/

Executive Leadership

Dawn A. Svoronos

Independent Chairman of the Board

Luc Tanguay

President, Chief Executive Officer, Director

Philippe Dubuc

Chief Financial Officer, Senior Vice President

Jovan Antunovic

Senior Vice President and Chief Commercial Office

Christian Marsolais

Senior Vice President - Scientific Affairs and Alliances

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

0.007

2017

-0.186

2018

-0.047

2019(E)

-0.060
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.67
Price To Book (MRQ)
9.45
Price To Cash Flow (TTM)
1,129.53
Total Debt To Equity (MRQ)
178.97
LT Debt To Equity (MRQ)
167.71
Return on Investment (TTM)
-8.52
Return on Equity (TTM)
-6.50

Latest News

Latest News

BRIEF-FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA

* FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)

BRIEF-Theratechnologies To Seek Regulatory Approval Of Trogarzo In Europe

* THERATECHNOLOGIES TO SEEK REGULATORY APPROVAL OF TROGARZO™ (IBALIZUMAB) IN EUROPE

BRIEF-Theratechnologies Reports Q1 Loss Per Share C$0.04

* THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018

BRIEF-Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection

* THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZO™ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1 Source text for Eikon: Further company coverage:

BRIEF-Theratechnologies Reports Q4 Loss Per Share Of C$0.06

* THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017

BRIEF-Theratechnologies Q3 loss per share c$0.04

* Theratechnologies announces financial results for third quarter of 2017

BRIEF-Theratechnologies announces new findings with investigational Antiretroviral Ibalizumab, with EGRIFTA

* Theratechnologies Inc - announces new findings with investigational Antiretroviral Ibalizumab and with EGRIFTA

BRIEF-Theratechnologies reports Q2 loss per share C$0.13

* Theratechnologies announces financial results for second quarter of 2017

BRIEF-Theratechnologies says FDA sets PDUFA date of Jan 3 for ibalizumab application

* FDA grants priority review to HIV monoclonal antibody and long-acting investigational antiretroviral ibalizumab

BRIEF-Theratechnologies partner Taimed submits biologics license application for Ibalizumab

* Theratechnologies partner submits biologics license application for HIV Monoclonal Antibody and long-acting investigational antiretroviral Ibalizumab

BRIEF-Theratechnologies Q1 loss per share C$0.03

* Theratechnologies announces financial results for first quarter of 2017

BRIEF-Theratechnologies Q1 loss per share C$0.03

* Theratechnologies announces financial results for first quarter of 2017

BRIEF-Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories

* Theratechnologies inc - agreement also includes upfront payment of US$3m payable through issuance of 906,077 common shares of Theratechnologies

BRIEF-Theratechnologies announces new data from the pivotal phase III trial of Ibalizumab

* Theratechnologies announces new data from the pivotal phase III trial of HIV monoclonal antibody and long-acting investigational antiretroviral Ibalizumab

BRIEF-Theratechnologies posts Q4 earnings per share C$0.00

* Theratechnologies announces financial results for fiscal year 2016

BRIEF-Theratechnologies-Abstract submitted by Taimed for 24-week study of Ibalizumab phase III

* Theratechnologies-Abstract submitted by its partner, Taimed Biologics, for 24-week study of Ibalizumab phase III study has been selected for late breaker presentation Source text for Eikon: Further company coverage:

BRIEF-Theratechnologies announces filing of final short form prospectus

* Theratechnologies announces the filing of a final short form prospectus Source text for Eikon: Further company coverage:

BRIEF-Theratechnologies announces $16.5 mln bought deal financing

* Theratechnologies announces $16.5 million bought deal financing

BRIEF-Theratechnologies announces end of patient treatment for late-stage ibalizumab trial

* Announces end of patient treatment for phase III ibalizumab trial Source text for Eikon: Further company coverage:

BRIEF-Theratechnologies Inc Q3 EPS C$0.01

* Theratechnologies announces financial results for third quarter of 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up